The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.
March 6th 2024
The FDA has approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
The Latest on Acute Lymphocytic Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
A Focus on Acute Myeloid Leukemia
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
The FDA has issued a complete response letter to Fennec Pharmaceuticals regarding its new drug application for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.
FDA Grants Pedmark Priority Review for Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors
The FDA has granted a priority review designation to a new drug application for a unique formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.
FDA Approval Sought for Omburtamab in Pediatric Metastatic Neuroblastoma
The biologics license application for the investigational B7-H3–targeting monoclonal antibody omburtamab for use in pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been submitted to the FDA under the agency’s Rolling Review process.
FDA Sets Review Date for Remestemcel-L for Steroid-Refractory Pediatric Acute GVHD
The FDA’s Oncologic Drugs Advisory Committee has scheduled a date to review data supporting the biologics license application for remestemcel-L as a treatment for children with steroid-refractory acute graft versus host disease.
FDA Grants Naxitamab Priority Review for Relapsed/Refractory High-Risk Neuroblastoma
The FDA has granted a priority review designation to a biologics license application for the investigational, humanized monoclonal antibody naxitamab (Danyelza) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.
Using a Multinational Pediatric Cancer Registry Helps to Improve PFS in High-Risk Patients
May 29th 2020The use of real-time comprehensive profiling provides valuable diagnostic information and identifies potential therapeutic targets in adults with malignancies, but this process remains widely underutilized for pediatric patients and represents a significant unmet need.
Dr. van Tilburg on Larotrectinib in TRK+ Pediatric Cancers
July 2nd 2019Cornelis M. van Tilburg, MD, PhD, pediatric oncologist, Hopp Children’s Cancer Center Heidelberg, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive cancers who have brain metastases or primary central nervous system tumors.
Larotrectinib Effective in TRK+ Pediatric Cancers and CNS Tumors
The efficacy of larotrectinib is supported in distinct patient populations with TRK fusion cancer—specifically pediatric patients and adult or pediatric patients with brain metastases or primary central nervous system tumors.
Dr. Sweetenham on Unanswered Questions With CAR T-Cell Therapy in Pediatric ALL
June 1st 2019John Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.
Pediatric Precision Medicine Approach Proven Possible in Pediatric MATCH Trial
About a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration of pathway in the screening protocol of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial.
Risk Factor Profile Determined for Development of Pediatric TA-TMA After HSCT
April 3rd 2019The development of high-grade acute graft-versus-host disease following hematopoietic stem cell transplantation poses the highest risk for transplant-associated thrombotic microangiopathy in pediatric patients.
Childhood Cancer Substantially Underdiagnosed Worldwide
March 21st 2019Childhood cancer is significantly underdiagnosed—especially in south Asia and sub-Saharan Africa—underscoring the need for stronger health systems and the expansion of universal health coverage, according to an analysis published in Lancet Oncology.
Dr. Pikman on Implications of a Matched Targeted Therapy Approach in Pediatric Leukemia
February 28th 2019Yana Pikman, MD, a physician in the Cancer and Blood Disorders Center at Dana-Farber Cancer Institute and instructor of pediatrics at Harvard Medical School, discusses the implications of a matched targeted therapy approach in pediatric leukemia.
Study Confirms Long-Term Risk of Secondary Cancers in Pediatric Hodgkin Lymphoma Survivors
February 7th 2019The relative risk of developing a solid subsequent malignant neoplasm remained elevated in survivors of childhood Hodgkin lymphoma, according to extended follow-up of more than 25 years from the Late Effects Study Group cohort.
Dr. Summers on Role of CAR T Cells in Pediatric Cancer
December 29th 2018Corinne Summers, MD, pediatric oncologist, Seattle Children's Hospital, assistant member, Clinical Research Division, University of Washington Fred Hutchinson Cancer Research Center, discusses the role of CAR T cells in pediatric cancer.